CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Operating expenses:
General and administrative	$ 5	$ 1,770,116	$ 12,720,666	$ 5,432,773
Research and development	1,684,783	564,145	5,130,561	2,162,680
In-process research and development (IPR&D) - Teverelix	8,717,475	0	8,717,475	0
Total operating expenses	15	2,334,261	26,568,702	7,595,453
Loss from operations	(15)	(2,334,261)	(26,568,702)	(7,595,453)
Other income (expense)
Interest income (expense)	11,572	55,514	75,442	(23,511)
Loss on SEPA settlements	(157,721)	0	(157,721)	0
Change in fair value of debentures	(383,823)	0	(583,823)	0
Loss on extinguishment of debentures	(25,000)	0	(25,000)	0
Total other income (expense)	(554,972)	55,514	(691,102)	(23,511)
Net loss for the period	(15,981,312)	(2,278,747)	(27,259,804)	(7,618,964)
Deemed dividend on warrant inducement	(4,954,518)	0	(4,954,518)	0
Net loss for the period attributable to common shareholders		(2,278,747)	(32,214,322)	(7,618,964)
Foreign currency translation adjustment	10,828	0	10,828	0
Comprehensive loss for the period	(2)	(2,278,747)	(32,203,494)	(7,618,964)
Net loss attributable to:
Common shareholders of the Company	(20,935,753)	(2,278,747)	(32,214,245)	(7,618,964)
Non-controlling interests	(77)	0	(77)	0
Comprehensive loss attributable to:
Common shareholders of the Company	(20,925,077)	(2,278,747)	(32,203,569)	(7,618,964)
Non-controlling interests	$ 75	$ 0	$ 75	$ 0
Net loss per share attributable to common shareholders - basic	$ (1.12)	$ (0.24)	$ (1.91)	$ (0.84)
Net loss per share attributable to common shareholders - diluted	$ (1.12)	$ (0.24)	$ (1.91)	$ (0.84)
Weighted average number of common shares outstanding - basic	18,631,668	9,514,738	16,844,607	9,037,153
Weighted average number of common shares outstanding - diluted	18,631,668	9,514,738	16,844,607	9,037,153